login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

Avinger’s Ocelot catheter is CE marked


Thursday, 29 Sep 2011 11:21

Avinger has received CE mark approval for Ocelot ― a peripheral catheter system used with real-time Optical Coherence Tomography (OCT) for the treatment of peripheral artery disease.


According to Avinger, medical professionals, for the first time ever, will have access to a therapeutic device that incorporates real time intravascular guidance by using Ocelot’s Lightbox console as an adjunct to fluoroscopy.


“Ocelot CE mark is a long anticipated milestone for Avinger and a much larger milestone for me professionally. I have been working on uniting intravascular guidance with therapeutic products for 30 years and I am humbled that we have been able to achieve this at Avinger,” said John B Simpson, Avinger’s founder and CEO.


Avinger is currently enrolling patients in the VISTA study ― a single-centre, non-randomised registry designed to evaluate the safety and efficacy of Ocelot in patients with peripheral artery disease. The registry is being developed in Paraguay, with Adrian Ebner of Sanitorio Italiano in Asunción, as the principal investigator.


European comercialisation of Ocelot has already begun. The first three commercial cases are scheduled to be performed in Italy and Germany in late September and early October.

 




Add New Comment

Most popular


Cyanoacrylate embolisation agent non-inferior to radiofrequency ablation for incompetent great saphenous veins treatment
Friday, 03 Jul 2015
Twelve-month results from the VeClose trial have demonstrated cyanoacrylate adhesive (CAE) is non-inferior to radiofrequency ablation (RFA) for the treatment of incompetent great saphenous veins. Cyanoacrylate embolisation agent non-inferior to radiofrequency ablation for incompetent great saphenous veins treatment

Biolas introduces VariClose in Europe
Thursday, 16 Jul 2015
After the European launch in April 2015, Biolas has introduced the VariClose Vein Sealing Systems in the European market for the treatment of varicose veins. Biolas introduces VariClose in Europe

Lombard Medical acquires EVAR stent graft developer Altura Medical
Friday, 31 Jul 2015
Altura Medical has developed an ultra-low profile endovascular stent graft technology that, according to Lombard, offers a simple and predictable solution for the treatment of standard abdominal ... Lombard Medical acquires EVAR stent graft developer Altura Medical

Features


Patient selection is key for SIRT with first-line chemotherapy
Tuesday, 18 Aug 2015
Ricky Sharma, professor and honorary consultant of Clinical Oncology at the University of Oxford and Oxford University Hospitals Trust tells Interventional News: “We need to know more about patient ... Patient selection is key for SIRT with first-line chemotherapy

Choosing horses for courses: Using liquid agents to embolize endoleaks
Monday, 27 Jul 2015
Robert Morgan, vascular interventional radiologist, St Georges Hospital, London, UK, tells Interventional News why he uses liquid embolic agents, such as ethylene vinyl oxide copolymer (EVOH-based) ... Choosing horses for courses: Using liquid agents to embolize endoleaks

Profiles


Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions